Art
J-GLOBAL ID:200902188474857620   Reference number:00A0514027

Identification and Characterization of a Deletion Mutant of DNA Topoisomerase I mRNA in a Camptothecin-resistant Subline of Human Colon Carcinoma.

ヒト結腸癌細胞のカンプトテシン抵抗性株におけるDNAトポイソメラーゼ1mRNA欠失変異の同定と特性指摘
Author (6):
Material:
Volume: 91  Issue:Page: 551-559  Publication year: May. 31, 2000 
JST Material Number: F0633A  ISSN: 0910-5050  Document type: Article
Article type: 原著論文  Country of issue: Japan (JPN)  Language: ENGLISH (EN)
Thesaurus term:
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
,...
   To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=00A0514027&from=J-GLOBAL&jstjournalNo=F0633A") }}
JST classification (1):
JST classification
Category name(code) classified by JST.
Basic research of antitumor(=antineoplastic)drugs 
Substance index (1):
Substance index
Chemical Substance indexed to the Article.
Reference (47):
  • GOTTLIEB, J. A. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep. 1970, 54, 461-470
  • GOTTLIEB, J. A. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep. 1972, 56, 103-105
  • MOERTEL, C. G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 1972, 56, 95-101
  • MUGGIA, F. M. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880); correlation with preclinical studies. Cancer Chemother. Rep. 1972, 56, 515-521
  • SCHAEPPI, U. Toxicity of camptothecin (NSC-100880). Cancer Chemother. Rep. Part 3. 1974, 5, 25-36
more...

Return to Previous Page